Patient baseline characteristics
| Characteristic . | Daily-to-weekly dosing (n = 32) . | All-daily dosing (n = 42) . | Total (N = 74) . |
|---|---|---|---|
| Age, median (range), y | 67 (41-89) | 69 (51-84) | 68 (41-89) |
| Male, n (%) | 15 (47) | 20 (48) | 35 (47) |
| Race, n (%) | |||
| White | 25 (78) | 35 (83) | 60 (81) |
| Other∗ | 7 (22) | 7 (17) | 14 (19) |
| Time since first myelofibrosis diagnosis, mo, median (range) | 30.5 (6.7-268.9) | 37.5 (4.9-251.5) | 33.0 (4.9-268.9) |
| Ruxolitinib use, median (range) | |||
| Daily dose, mg | 28.9 (13.8-50.0) | 29.3 (8.7-44.8) | 29.3 (8.7-50.0) |
| Duration, mo | 18.1 (3.7-93.9) | 16.4 (5.1-105.5) | 17.2 (3.7-105.5) |
| Palpable spleen, n | 31 | 42 | 73 |
| Median length, cm (range) | 14 (8-30) | 11 (5-30) | 13 (5-30) |
| SV, n | 29 | 37 | 66 |
| Median, cm3 (range) | 2414.5 (327.1-5323.7) | 1877.5 (434.2-3904.1) | 1972.5 (327.1-5323.7) |
| Total symptom score by MFSAF, n | 28 | 32 | 60 |
| Median (range) | 10.8 (0-47.0) | 16.3 (0.6-38.4) | 13.6 (0-47.0) |
| Total symptom score by MPN-SAF, n | 28 | 37 | 65 |
| Median (range) | 25.5 (0-83.0) | 30.0 (3.0-65.0) | 29.0 (0-83.0) |
| Hemoglobin, g/L, median (range) | 102 (70-159) | 98 (57-155) | 100 (57-159) |
| DIPSS risk level at baseline, n (%) | |||
| High | 5 (16) | 10 (24) | 15 (20) |
| Intermediate-2 | 10 (31) | 19 (45) | 29 (39) |
| Intermediate-1 | 13 (41) | 12 (29) | 25 (34) |
| Low | 4 (12.5) | 1 (2) | 5 (7) |
| Myelofibrosis type, n (%) | |||
| PMF | 17 (53) | 23 (55) | 40 (54) |
| PPV-MF | 12 (38) | 12 (29) | 24 (32) |
| PET-MF | 3 (9) | 7 (17) | 10 (14) |
| Characteristic . | Daily-to-weekly dosing (n = 32) . | All-daily dosing (n = 42) . | Total (N = 74) . |
|---|---|---|---|
| Age, median (range), y | 67 (41-89) | 69 (51-84) | 68 (41-89) |
| Male, n (%) | 15 (47) | 20 (48) | 35 (47) |
| Race, n (%) | |||
| White | 25 (78) | 35 (83) | 60 (81) |
| Other∗ | 7 (22) | 7 (17) | 14 (19) |
| Time since first myelofibrosis diagnosis, mo, median (range) | 30.5 (6.7-268.9) | 37.5 (4.9-251.5) | 33.0 (4.9-268.9) |
| Ruxolitinib use, median (range) | |||
| Daily dose, mg | 28.9 (13.8-50.0) | 29.3 (8.7-44.8) | 29.3 (8.7-50.0) |
| Duration, mo | 18.1 (3.7-93.9) | 16.4 (5.1-105.5) | 17.2 (3.7-105.5) |
| Palpable spleen, n | 31 | 42 | 73 |
| Median length, cm (range) | 14 (8-30) | 11 (5-30) | 13 (5-30) |
| SV, n | 29 | 37 | 66 |
| Median, cm3 (range) | 2414.5 (327.1-5323.7) | 1877.5 (434.2-3904.1) | 1972.5 (327.1-5323.7) |
| Total symptom score by MFSAF, n | 28 | 32 | 60 |
| Median (range) | 10.8 (0-47.0) | 16.3 (0.6-38.4) | 13.6 (0-47.0) |
| Total symptom score by MPN-SAF, n | 28 | 37 | 65 |
| Median (range) | 25.5 (0-83.0) | 30.0 (3.0-65.0) | 29.0 (0-83.0) |
| Hemoglobin, g/L, median (range) | 102 (70-159) | 98 (57-155) | 100 (57-159) |
| DIPSS risk level at baseline, n (%) | |||
| High | 5 (16) | 10 (24) | 15 (20) |
| Intermediate-2 | 10 (31) | 19 (45) | 29 (39) |
| Intermediate-1 | 13 (41) | 12 (29) | 25 (34) |
| Low | 4 (12.5) | 1 (2) | 5 (7) |
| Myelofibrosis type, n (%) | |||
| PMF | 17 (53) | 23 (55) | 40 (54) |
| PPV-MF | 12 (38) | 12 (29) | 24 (32) |
| PET-MF | 3 (9) | 7 (17) | 10 (14) |
DIPSS, Dynamic International Prognostic Scoring System; PET-MF, post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; PPV-MF, post–polycythemia vera myelofibrosis; SV, spleen volume.
Includes Black/African American, Asian, and Other.